Skip to main content
Premium Trial:

Request an Annual Quote

Broad Institute Licenses CRISPR/Cas9 IP to Transposagen

NEW YORK (GenomeWeb) – Transposagen announced today that it has licensed CRISPR/Cas9 intellectual property from the Broad Institute.

With the non-exclusive license agreement, Transposagen will be able to combine CRISPR/Cas9 genome editing technology with its Footprint-Free Gene Editing System. The combination allows for "precision gene editing without fear of undesired off-target effects," Transposagen CEO John Printen said in a statement.

Lexington, Kentucky-based Transposagen is commercializing gene editing technologies to aid both basic research and drug discovery. The firm has licensed piggyBac transposon technology for almost all commercial applications.

It's the latest CRISPR IP licensing agreement for the Broad, which has also licensed the technology to Horizon Discovery, GE Healthcare, and Sigma-Aldrich.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.